Cardiogen (AEDR)
Also known as Cardiogen · AEDR · Ala-Glu-Asp-Arg · CardioCytogen
New
Reconstitution & dosing guide
20 mg vial — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only20mg x 10 vials
Cardiogen · Not in current stock
$50 / vial
Prices per vial · Research use only · Not medical advice.
Khavinson-class tetrapeptide bioregulator (Ala-Glu-Asp-Arg) studied for cardiomyocyte gene regulation, anti-apoptosis, and cardiac tissue support in Russian bioregulator literature.
How to picture it
Short bioregulator peptides are framed less like sledgehammers and more like tissue-addressed memos. Cardiogen is studied as a cardiac-directed note — a brief sequence associated with heart-tissue gene programs in the Khavinson tradition. Picture a password aimed at cardiac maintenance language instead of flooding the whole system. Evidence style differs from Western drug RCTs; the educational idea is organ-preferential short-peptide signaling.
Research focus & benefits
- Cardiac bioregulator research tradition
- Tissue-directed short-peptide gene-program interest
- Heart-maintenance pathway studies
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Cardiogen is a synthetic tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology as the cardiac-specific member of the ultrashort peptide bioregulator family. It shares the Ala-Glu-Asp core with Epitalon and Cortagen, with C-terminal arginine conferring claimed cardiac tissue selectivity. Western independent replication is limited; most primary data come from the Khavinson group.
Mechanism
Proposed epigenetic bioregulator mechanism: nuclear entry, DNA/histone interaction (H1, H2B, H3, H4), chromatin decondensation, and tissue-specific gene reactivation in cardiomyocytes. Organotypic myocardial cultures report stimulated cardiomyocyte proliferation with p53 downregulation and upregulation of cytoskeletal/nuclear matrix proteins. Also discussed in SASP/inflammaging cardiovascular reviews from the same group.
Research uses
- Cardiomyocyte proliferation and anti-apoptosis in organotypic cultures
- Cardiac fibrosis and remodeling models (preclinical)
- SASP / cardiovascular inflammaging hypothesis papers
- Comparative Khavinson bioregulator tissue-specificity studies
Research dosing notes
Bioregulator cyclic protocols in Russian literature typically use multi-day courses at low milligram totals. No FDA-validated regimen.
Half-life / kinetics
Ultrashort peptide — plasma minutes; proposed transcriptional effects longer
Common research routes
Reported considerations
- Limited Western safety dataset
- Unknown interactions with cardiac drugs
Contraindications / cautions
- Active cardiac emergency — seek standard care
- Pregnancy
- Do not replace proven cardiology therapy
Common research stacks
- Epitalon
- Cortagen
- Thymalin
- Vesugen
Legal / access note
Not FDA-evaluated. Sold as research peptide / Russian bioregulator class. Not a substitute for cardiovascular medicine.